Proteins kinase Cε is required for non-small cell lung carcinoma growth and regulates the expression of apoptotic genes

Oncogene

Volumn 31, Issue 20, 2012, Pages 2593-2600

  Caino, M C ^a   Lopez Haber, C ^a   Kim, J ^b   Mochly Rosen, D ^c   Kazanietz, M G ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b STANFORD CANCER INSTITUTE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

apoptotic genes; cell survival; non small cell lung carcinoma; PKC ; tumorigenesis

Indexed keywords

PROTEIN BCL 2; PROTEIN KINASE C EPSILON; PROTEIN KINASE C INHIBITOR; SHORT HAIRPIN RNA; EPSILONV1 2 PEPTIDE; EPSILONV1-2 PEPTIDE; PEPTIDE FRAGMENT; PROTEIN KINASE C; PROTEIN KINASE INHIBITOR; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL SURVIVAL; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; ANIMAL; CANCER TRANSPLANTATION; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; LUNG TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; PROTO ONCOGENE;

MUS;

ANIMALS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; CELL SURVIVAL; GENES, BCL-2; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PEPTIDE FRAGMENTS; PROTEIN KINASE C; PROTEIN KINASE C-EPSILON; PROTEIN KINASE INHIBITORS; RECEPTORS, TUMOR NECROSIS FACTOR; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84861379628     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.428     Document Type: Article

References (47)

1. Bae KM, Wang H, Jiang G, Chen MG, Lu L, Xiao L. (2007). Protein kinase C epsilon is overexpressed in primary human non-small cell lung cancers and functionally required for proliferation of nonsmall cell lung cancer cells in a p21/Cip1-dependent manner. Cancer Res 67: 6053-6063. (Pubitemid 47037484)
2. Bain J, McLauchlan H, Elliott M, Cohen P. (2003). The specificities of protein kinase inhibitors: an update. Biochem J 371(Pt 1): 199-204. (Pubitemid 36458094)
3. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H et al. (2007). The selectivity of protein kinase inhibitors: a further update. Biochem J 408: 297-315.
4. Barr LF, Mabry M, Nelkin BD, Tyler G, May WS, Baylin SB. (1991). c-myc gene-induced alterations in protein kinase C expression: a possible mechanism facilitating myc-ras gene complementation. Cancer Res 51: 5514-5519.
5. Barry OP, Kazanietz MG. (2001). Protein kinase C isozymes, novel phorbol ester receptors and cancer chemotherapy. Curr Pharm Des 7: 1725-1744. (Pubitemid 32998335)
6. Basu A, Sivaprasad U. (2007). Protein kinase C epsilon makes the life and death decision. Cell Signal 19: 1633-1642. (Pubitemid 46935437)
7. Begley R, Liron T, Baryza J, Mochly-Rosen D. (2004). Biodistribution of intracellularly acting peptides conjugated reversibly to Tat. Biochem Biophys Res Commun 318: 949-954. (Pubitemid 38625866)
8. Benavides F, Blando J, Perez CJ, Garg R, Conti CJ, DiGiovanni J et al. (2011). Transgenic overexpression of PKC epsilon in the mouse prostate induces preneoplastic lesions. Cell Cycle 10: 268-277.
9. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P et al. (2001). Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 98: 13790-13795. (Pubitemid 33115977)
10. Black JD. (2000). Protein kinase C-mediated regulation of the cell cycle. Front Biosci 5: D406-D423.
11. Brodie C, Blumberg PM. (2003). Regulation of cell apoptosis by protein kinase c delta. Apoptosis 8: 19-27. (Pubitemid 36133134)
12. Budas GR, Koyanagi T, Churchill EN, Mochly-Rosen D. (2007). Competitive inhibitors and allosteric activators of protein kinase C isoenzymes: a personal account and progress report on transferring academic discoveries to the clinic. Biochem Soc Trans 35(Pt 5): 1021-1026. (Pubitemid 350206418)
13. Caino MC, Meshki J, Kazanietz MG. (2009). Hallmarks for senescence in carcinogenesis: novel signaling players. Apoptosis 14: 392-408.
14. Caino MC, von Burstin VA, Lopez-Haber C, Kazanietz MG. (2011). Differential regulation of gene expression by protein kinase C isozymes as determined by genome-wide expression analysis. J Biol Chem 286: 11254-11264.
15. Davies SP, Reddy H, Caivano M, Cohen P. (2000). Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351(Pt 1): 95-105.
16. Felber M, Sonnemann J, Beck JF. (2007). Inhibition of novel protein kinase C-epsilon augments TRAIL-induced cell death in A549 lung cancer cells. Pathol Oncol Res 13: 295-301. (Pubitemid 351287310)
17. Fleischman LF, Chahwala SB, Cantley L. (1986). Ras-transformed cells: altered levels of phosphatidylinositol-4,5-bisphosphate and catabolites. Science 231: 407-410. (Pubitemid 16108653)
18. Goekjian PG, Jirousek MR. (2001). Protein kinase C inhibitors as novel anticancer drugs. Expert Opin Investig Drugs 10: 2117-2140. (Pubitemid 34000377)
19. Gorin MA, Pan Q. (2009). Protein kinase C epsilon: an oncogene and emerging tumor biomarker. Mol Cancer 8: 9.
20. Gray MO, Karliner JS, Mochly-Rosen D. (1997). A selective epsilonprotein kinase C antagonist inhibits protection of cardiac myocytes from hypoxia-induced cell death. J Biol Chem 272: 30945-30951. (Pubitemid 27527538)
21. Griner EM, Kazanietz MG. (2007). Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 7: 281.
22. Han EK, Cacace AM, Sgambato A, Weinstein IB. (1995). Altered expression of cyclins and c-fos in R6 cells that overproduce PKC epsilon. Carcinogenesis 16: 2423-2428.
23. Hsiao WL, Housey GM, Johnson MD, Weinstein IB. (1989). Cells that overproduce protein kinase C are more susceptible to transformation by an activated H-ras oncogene. Mol Cell Biol 9: 2641-2647. (Pubitemid 19148139)
24. Inagaki K, Begley R, Ikeno F, Mochly-Rosen D. (2005). Cardioprotection by epsilon-protein kinase C activation from ischemia: continuous delivery and antiarrhythmic effect of an epsilon-protein kinase C-activating peptide. Circulation 111: 44-50. (Pubitemid 40070842)
25. Jansen AP, Verwiebe EG, Dreckschmidt NE, Wheeler DL, Oberley TD, Verma AK. (2001). Protein kinase C-epsilon transgenic mice: a unique model for metastatic squamous cell carcinoma. Cancer Res 61: 808-812. (Pubitemid 32174382)
26. Koyanagi T, Noguchi K, Ootani A, Inagaki K, Robbins RC, Mochly-Rosen D. (2007). Pharmacological inhibition of epsilon PKC suppresses chronic inflammation in murine cardiac transplantation model. J Mol Cell Cardiol 43: 517-522. (Pubitemid 47451418)
27. Lemmon MA, Schlessinger J. (2010). Cell signaling by receptor tyrosine kinases. Cell 141: 1117-1134.
28. Lu D, Huang J, Basu A. (2006). Protein kinase C\{epsilon\} activates prote. J Biol Chem 281: 22799-22807.
29. Malumbres M, Barbacid M. (2003). RAS oncogenes: the first 30 years. Nat Rev Cancer 3: 459-465. (Pubitemid 37328850)
30. Matyas GR, Fishman PH. (1989). Lipid signalling pathways in normal and ras-transfected NIH/3T3 cells. Cell Signal 1: 395-404. (Pubitemid 19209839)
31. McJilton MA, Van Sikes C, Wescott GG, Wu D, Foreman TL, Gregory CW et al. (2003). Protein kinase C epsilon interacts with Bax and promotes survival of human prostate cancer cells. Oncogene 22: 7958-7968. (Pubitemid 37175861)
32. Mischak H, Goodnight JA, Kolch W, Martiny-Baron G, Schaechtle C, Kazanietz MG et al. (1993). Overexpression of protein kinase Cdelta and-epsilon in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence, and tumorigenicity. J Biol Chem 268: 6090-6096. (Pubitemid 23099293)
33. Mochly-Rosen D, Kauvar LM. (1998). Modulating protein kinase C signal transduction. Adv Pharmacol 44: 91-145.
34. Nakagawa M, Oliva JL, Kothapalli D, Fournier A, Assoian RK, Kazanietz MG. (2005). Phorbol ester-induced G1 phase arrest selectively mediated by protein kinase C delta-dependent induction of p21. J Biol Chem 280: 33926-33934. (Pubitemid 41443112)
35. Okhrimenko H, Lu W, Xiang C, Hamburger N, Kazimirsky G, Brodie C. (2005). Protein kinase C-epsilon regulates the apoptosis and survival of glioma cells. Cancer Res 65: 7301-7309. (Pubitemid 41161262)
36. Oliva JL, Caino MC, Senderowicz AM, Kazanietz MG. (2008). S-Phase-specific activation of PKC alpha induces senescence in non-small cell lung cancer cells. J Biol Chem 283: 5466-5476.
37. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500. (Pubitemid 38720929)
38. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I et al. (2004). EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311. (Pubitemid 39209661)
39. Parker PJ, Murray-Rust J. (2004). PKC at a glance. J Cell Sci 117(Pt 2): 131-132. (Pubitemid 38128893)
40. Perletti GP, Folini M, Lin HC, Mischak H, Piccinini F, Tashjian Jr AH. (1996). Overexpression of protein kinase C epsilon is oncogenic in rat colonic epithelial cells. Oncogene 12: 847-854. (Pubitemid 26072270)
41. Preiss J, Loomis CR, Bishop WR, Stein R, Niedel JE, Bell RM. (1986). Quantitative measurement of sn-1,2-diacylglycerols present in platelets, hepatocytes, and ras-and sis-transformed normal rat kidney cells. J Biol Chem 261: 8597-8600. (Pubitemid 17205050)
42. Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, Hoda S et al. (1993). Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 53(10 Suppl): 2379-2385. (Pubitemid 23156828)
43. Sekido Y, Fong KM, Minna JD. (2003). Molecular genetics of lung cancer. Annu Rev Med 54: 73-87. (Pubitemid 37386386)
44. Serova M, Ghoul A, Benhadji KA, Cvitkovic E, Faivre S, Calvo F et al. (2006). Preclinical and clinical development of novel agents that target the protein kinase C family. Semin Oncol 33: 466-478. (Pubitemid 44160726)
45. Slupsky JR, Kamiguti AS, Harris RJ, Cawley JC, Zuzel M. (2007). Central role of protein kinase C epsilon in constitutive activation of ERK1/2 and Rac1 in the malignant cells of hairy cell leukemia. Am J Pathol 170: 745-754. (Pubitemid 47339408)
46. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102: 15545-15550. (Pubitemid 41528093)
47. Toker A. (1998). Signaling through protein kinase C. Front Biosci 3: D1134-D1147.